Compare QTTB & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTTB | MYO |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.3M | 36.9M |
| IPO Year | N/A | 2017 |
| Metric | QTTB | MYO |
|---|---|---|
| Price | $3.60 | $0.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $7.33 | ★ $7.67 |
| AVG Volume (30 Days) | 152.2K | ★ 589.2K |
| Earning Date | 03-10-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,643,203.00 |
| Revenue This Year | N/A | $24.07 |
| Revenue Next Year | N/A | $17.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 65.00 |
| 52 Week Low | $1.35 | $0.71 |
| 52 Week High | $6.37 | $6.44 |
| Indicator | QTTB | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 49.31 |
| Support Level | $3.22 | $0.90 |
| Resistance Level | $3.73 | $1.05 |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 73.95 | 30.85 |
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).